Literature DB >> 18570754

HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity.

F Croce1, S Piconi, F Atzeni, P Sarzi-Puttini, M Galli, M Clerici.   

Abstract

Human Immunodeficiency Virus (HIV) infection represents one of the most serious challenges to global public health, since more than 30 million people are living with HIV/AIDS worldwide. Highly active antiretroviral treatment (HAART) introduction has dramatically changed the mortality and morbidity of HIV-affected subjects in industrialized countries but has implied an evolution of many HIV-related aspects, both in the utilisation of new antiretroviral drugs options and in the newly-observed spectrum of HIV-associated diseases, including the rheumatic pathology. Current epidemiological, therapeutic, autoimmune and rheumatic aspects of HIV-1 infection are here discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570754

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Authors:  Ming-Tain Lai; Meiqing Lu; Peter J Felock; Renee C Hrin; Ying-Jie Wang; Youwei Yan; Sanjeev Munshi; Georgia B McGaughey; Robert M Tynebor; Thomas J Tucker; Theresa M Williams; Jay A Grobler; Daria J Hazuda; Philip M McKenna; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

Review 2.  Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review.

Authors:  Bahati Mk Wajanga; Lauren E Webster; Robert N Peck; Jennifer A Downs; Kedar Mate; Luke R Smart; Daniel W Fitzgerald
Journal:  BMC Health Serv Res       Date:  2014-12-03       Impact factor: 2.655

Review 3.  Trichomonas vaginalis screening and prevention in order to impact the HIV pandemic: Isn't it time we take this infection seriously?

Authors:  Gweneth B Lazenby
Journal:  Infect Dis Rep       Date:  2011-04-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.